Regeneron Pharmaceuticals (NASDAQ:REGN) EVP Joseph Larosa Sells 4,466 Shares of Company Stock

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) EVP Joseph Larosa sold 4,466 shares of the company’s stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $965.49, for a total transaction of $4,311,878.34. Following the sale, the executive vice president directly owned 38,906 shares of the company’s stock, valued at approximately $37,563,353.94. This trade represents a 10.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Regeneron Pharmaceuticals Stock Down 4.4%

NASDAQ REGN traded down $42.69 on Wednesday, reaching $930.67. The company had a trading volume of 1,383,115 shares, compared to its average volume of 830,923. The firm has a market capitalization of $95.82 billion, a PE ratio of 20.55, a P/E/G ratio of 1.51 and a beta of 0.10. Regeneron Pharmaceuticals, Inc. has a 1 year low of $591.52 and a 1 year high of $991.73. The firm has a 50-day moving average of $798.74 and a 200-day moving average of $740.16. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.35 and a quick ratio of 3.66.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, beating the consensus estimate of $16.51 by $3.56. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The company had revenue of $5.12 billion during the quarter, compared to analysts’ expectations of $4.58 billion. During the same period in the prior year, the business posted $11.83 EPS. The business’s revenue was up 36.3% on a year-over-year basis. On average, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 49.10 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 3rd. Shareholders of record on Friday, November 20th will be given a $0.94 dividend. The ex-dividend date is Friday, November 20th. This represents a $3.76 annualized dividend and a yield of 0.4%. Regeneron Pharmaceuticals’s dividend payout ratio is 8.30%.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. BlackRock Inc. bought a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at about $5,682,636,000. State Street Corp raised its holdings in shares of Regeneron Pharmaceuticals by 3.6% in the 2nd quarter. State Street Corp now owns 4,834,688 shares of the biopharmaceutical company’s stock worth $3,014,621,000 after purchasing an additional 170,210 shares in the last quarter. Bank of America Corp DE raised its holdings in shares of Regeneron Pharmaceuticals by 2.8% in the 1st quarter. Bank of America Corp DE now owns 1,189,584 shares of the biopharmaceutical company’s stock worth $919,120,000 after purchasing an additional 32,158 shares in the last quarter. Amundi raised its holdings in shares of Regeneron Pharmaceuticals by 27.5% in the 1st quarter. Amundi now owns 1,009,798 shares of the biopharmaceutical company’s stock worth $780,210,000 after purchasing an additional 217,892 shares in the last quarter. Finally, Legal & General Group Plc acquired a new stake in Regeneron Pharmaceuticals during the second quarter valued at approximately $473,872,000. Institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Wells Fargo & Company increased their price target on Regeneron Pharmaceuticals from $750.00 to $925.00 and gave the stock an “equal weight” rating in a research note on Monday. Zacks Research raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, September 28th. Cantor Fitzgerald upped their price objective on shares of Regeneron Pharmaceuticals from $795.00 to $980.00 and gave the stock an “overweight” rating in a report on Monday. Weiss Ratings raised shares of Regeneron Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a research note on Monday. Finally, Morgan Stanley boosted their price target on shares of Regeneron Pharmaceuticals from $779.00 to $855.00 and gave the stock an “equal weight” rating in a research report on Monday. One research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $898.97.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Zacks says improving earnings estimates could help support further near-term gains in REGN shares, following the stock’s recent advance. Why Regeneron Might Be Well Poised for a Surge
• Positive Sentiment: Analysts have raised price targets and several firms have expressed confidence in further appreciation. This follows Regeneron’s strong third-quarter results: revenue rose 36.3% year over year to $5.12 billion and EPS of $20.07 beat consensus of $16.51. Coverage also cited commercial performance and pipeline progress. RBC raises its price target Cantor Fitzgerald outlook Q3 results and pipeline coverage
• Neutral Sentiment: Director Kathryn Guarini sold 400 shares for $360,000 under a pre-arranged Rule 10b5-1 plan. The planned sale is less informative as a signal about the company’s outlook. Director share sale
• Negative Sentiment: The recent rally may leave room for valuation-related caution: some analyst targets remain below the share price, even as other firms have lifted their forecasts. The articles do not identify a fresh company-specific setback behind Wednesday’s weakness.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.